SCHEMBL8403545

SCHEMBL8403545

CC(=O)Cc1ccc(CC(C)=O)cc1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.61
CA2 P00918 2/20 0.46
KMT2A Q03164 1/20 0.46
CAMK2A Q9UQM7 1/20 0.46
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43
AKR1B1 P15121 1/20 0.43
ALDH1A1 P00352 3/20 0.43
HPGD P15428 1/20 0.43
HSD17B10 Q99714 1/20 0.43
HTT P42858 2/20 0.42
ABCC4 O15439 1/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
TSHR P16473 1/20 0.42
PTGS1 P23219 1/20 0.42
CYP4F2 P78329 1/20 0.41
CYP4A11 Q02928 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10775630 0.92 POLB (0.55) POLBCA2KMT2ACAMK2AALDH1A1
SCHEMBL4455 0.89 CA2 (0.62) POLBCA2CAMK2AALDH1A1LMNA
SCHEMBL8277240 0.89 CA2 (0.62) POLBCA2KMT2ACAMK2AAKR1B1
SCHEMBL9149413 0.89 POLB (0.53) POLBCA2KMT2ACAMK2AALDH1A1
SCHEMBL5536012 0.89 POLB (0.53) POLBCA2KMT2ACAMK2ACES2
SCHEMBL564730 0.89 ALDH1A1 (0.54) POLBCA2KMT2AALDH1A1HPGD
SCHEMBL81559 0.89 CTBP2 (0.53) POLBKMT2AALDH1A1HPGDLMNA
SCHEMBL14495580 0.87 POLB (0.52) POLBCA2KMT2ACAMK2ACES2
SCHEMBL7151365 0.87 KMT2A (0.67) POLBKMT2AALDH1A1HPGDHSD17B10
Hydrochloric Acid SCHEMBL2583907 0.87 CA2 (0.60) POLBCA2CAMK2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357512-A1 RESIN COMPOSITION, MOLDED BODY, AND METHOD OF IMPROVING PROPERTY OF RESIN COMPOSITION IDEMITSU KOSAN CO.,LTD. (JP) 2023-11-09 US disclosed
US-20230331751-A1 STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES Atea Pharmaceuticals, Inc. (US) 2023-10-19 US disclosed
US-20230331751-A1 STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES Atea Pharmaceuticals, Inc. (US) 2023-10-19 US disclosed
US-11697708-B2 Polycarbonate-polyorganosiloxane copolymer, polycarbonate resin composition including same, and molded product thereof IDEMITSU KOSAN CO., LTD. (JP) 2023-07-11 US disclosed
US-11655326-B2 Molded body containing polycarbonate-polyorganosiloxane copolymer IDEMITSU KOSAN CO., LTD. (JP) 2023-05-23 US disclosed
US-20230151035-A1 Preparation method for and application of chiral spirocyclic phosphine-nitrogen-phosphine tridentate ligand and iridium catalyst thereof ZHEJIANG JIUZHOU PHARM CO LTD (CN) 2023-05-18 US disclosed
US-20230151035-A1 Preparation method for and application of chiral spirocyclic phosphine-nitrogen-phosphine tridentate ligand and iridium catalyst thereof ZHEJIANG JIUZHOU PHARM CO LTD (CN) 2023-05-18 US disclosed
EP-4089097-A1 PREPARATION METHOD FOR AND APPLICATION OF CHIRAL SPIROCYCLIC PHOSPHINE-NITROGEN-PHOSPHINE TRIDENTATE LIGAND AND IRIDIUM CATALYST THEREOF Zhejiang Jiuzhou Pharmaceutical Co., Ltd (CN) 2022-11-16 EP disclosed
US-11495744-B2 Organic semiconductor composition, organic thin film, and organic thin film transistor NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2022-11-08 US disclosed
CN-108109963-B Display unit, method of manufacturing the same, and electronic apparatus 索尼公司 2022-07-01 CN disclosed
US-20110242191-A1 INK COMPOSITION, INKJET RECORDING METHOD AND PROCESS FOR PRODUCING MOLDED PRINTED MATERIAL FUJIFILM CORPORATION (JP) 2011-10-06 US disclosed
US-7803804-B2 Substituted pyrazines for use in the treatment of inflammatory or allergic conditions NOVARTIS AG (CH) 2010-09-28 US disclosed
US-7803804-B2 Substituted pyrazines for use in the treatment of inflammatory or allergic conditions NOVARTIS AG (CH) 2010-09-28 US disclosed
US-20080312217-A1 Organic Compounds NOVARTIS AG 2008-12-18 US disclosed
US-20080312217-A1 Organic Compounds NOVARTIS AG 2008-12-18 US disclosed
WO-2007071396-A2 PYRAZINOYLGUANIDINE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS NOVARTIS AG (CH) 2007-06-28 WO disclosed
US-5153210-A Hypoglycemic agent, animal growth regulator; veterinary medicine BEECHAM GROUP P.L.C. (GB) 1992-10-06 US disclosed
EP-0236624-A2 Substituted phenyl ethanol amines, processes for their preparation and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1987-09-16 EP disclosed
EP-0196849-A2 Aminohydroxyalkylbenzene anti-obesity and/or anti-hyperglycaemic agents BEECHAM GROUP PLC (GB) 1986-10-08 EP disclosed
US-4555537-A IMIDAZOLINE DERIVATIVES AMERICAN CYANAMID COMPANY (US) 1985-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331751-A1 STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES NUDT1, PNP, ATIC POLB 503/4885CA2 1962/4885KMT2A 3176/4885
US-20080312217-A1 Organic Compounds TRPA1, TRPV1, CHRM1 POLB 3189/4885CA2 148/4885KMT2A 3363/4885
US-20230151035-A1 Preparation method for and application of chiral spirocyclic phosphine-nitrogen-phosphine tridentate ligand and iridium catalyst thereof SPR, PKD1, ROR1 POLB 3124/4885CA2 1844/4885KMT2A 3210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.